Autopsy report · NCT03871855

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

“Sponsor R \& D Strategy Adjustment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 years 2 months before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Sponsor type

Industry

Conditions

Advanced Solid Tumor

Interventions

SHR-1702; Camrelizumab

Participants

8

Sites

1

Countries

China

Trials that died the same way

• A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
  “Sponsor's R\&D strategy adjusted.” (92% match in meaning)
• Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies
  “The sponsor's R\&D strategy is adjusted.” (90% match in meaning)
• Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL
  “The sponsor has adjusted its R\&D strategy.” (89% match in meaning)
• Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
  “The Sponsor changed R\&D strategy and priority.” (81% match in meaning)
• Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
  “sponsor strategy change” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.